血清bFGF、VEGF与宫颈癌化疗敏感性及预后的关系

目的 探究血清碱性成纤维细胞生长因子（bFGF）、血管内皮生长因子（VEGF） 与宫颈癌化疗敏感性及预后的关系。方法 选取2017年1月~2019年3月在浙江省台州医院确诊的62例宫颈癌患者（宫颈癌组）及体检健康者62例（对照组），宫颈癌患者进行化疗治疗。分别检测宫颈癌组化疗前及化疗18周后、对照组健康体检时血清bFGF、VEGF水平，随访2年统计患者生存情况，分析宫颈癌患者化疗前血清bFGF、VEGF水平与临床病理参数及预后的关系。结果 62例宫颈癌患者化疗后，完全缓解49例（79.03 %），部分缓解9例（14.52 %），疾病稳定0例（0.00%），病情进展4例（6.45 %），总有效率为93.55 %。宫颈癌组化疗前血清bFGF、VEGF水平均显著高于对照组（P＜0.05）。Ⅱ A、Ⅱ B、Ⅲ A、Ⅲ B期宫颈癌患者化疗前血清bFGF、VEGF水平依次升高（P＜0.05）；低、中、高分化宫颈癌患者化疗前血清bFGF、VEGF水平依次降低（P＜0.05）；有淋巴结转移的宫颈癌患者化疗前血清bFGF、VEGF水平均显著高于无淋巴结转移患者（P＜0.05）。化疗前和化疗18周后完全缓解、部分缓解、病情进展患者血清bFGF、VEGF水平均依次升高（P＜0.05），与化疗前比较，部分缓解患者化疗18周后血清bFGF、VEGF水平均降低（P＜0.05）。bFGF、VEGF低水平组生存率分别显著高于bFGF、VEGF高水平组（P＜0.05）。结论 宫颈癌患者化疗前血清bFGF、VEGF水平呈高表达，二者水平与宫颈癌化疗敏感性及预后密切相关，血清bFGF、VEGF高水平患者预后较差，低水平患者预后较好。

Relationship between Serum bFGF, VEGF and Chemosensitivity and Prognosis of Cervical Cancer

Objective To explore the relationship between serum basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and chemosensitivity and prognosis of cervical cancer. Methods 62 cases of cervical cancer patients (cervical cancer group) and 62 healthy subjects (control group) in Taizhou Hospital of Zhejiang Province from January 2017 to March 2019 were selected as the objects, patients with cervical cancer were treated with chemotherapy. The levels of serum bFGF and VEGF were measured before and 18 weeks after chemotherapy in cervical cancer group and during physical examination in control group, followed up 2 years to count the survival rate of the disease, analyze the relationship between the levels of serum bFGF and VEGF and clinicopathological parameters and prognosis in patients with cervical cancer before chemotherapy. Results After chemotherapy in 62 patients with cervical cancer, there were 49 cases of complete remission (79.03%), 9 cases of partial remission (14.52%), 0 cases of stable disease (0.00%), 4 cases of disease progression (6.45%), and the total effective rate was 93.55%. The levels of serum bFGF and VEGF in cervical cancer group before chemotherapy were significantly higher than those in control group (P<0.05). The levels of serum bFGF and VEGF in patients with stage IIA, IIB, IIIa and IIB cervical cancer increased successively before chemotherapy (P<0.05); the levels of serum bFGF and VEGF in patients with low, medium and high differentiated cervical cancer decreased successively before chemotherapy (P<0.05); the levels of serum bFGF and VEGF in cervical cancer patients with lymph node metastasis before chemotherapy were significantly higher than those in patients without lymph node metastasis (P<0.05). The levels of serum bFGF and VEGF in patients with complete remission, partial remission and disease progression increased successively before and 18 weeks after chemotherapy (P<0.05); compared with those before chemotherapy, the levels of serum bFGF and VEGF in patients with partial remission decreased after 18 weeks of chemotherapy (P<0.05). The survival rates of bFGF and VEGF low level groups were significantly higher than those of bFGF and VEGF high level groups, respectively (P<0.05). Conclusion The levels of serum bFGF and VEGF were highly expressed in patients with cervical cancer before chemotherapy. Their levels were closely related to the chemosensitivity and prognosis of cervical cancer. The prognosis of patients with high levels of serum bFGF and VEGF was poor, and that of patients with low levels was better.